Login to Your Account

FDA Requires Confirmatory Trial For Dyax's HAE Drug

By Karen Pihl-Carey

Tuesday, September 5, 2006
Nearly four months after investors learned the FDA wanted more clinical data on Dyax Corp.'s hereditary angioedema drug DX-88, the agency recommended that the company complete a confirmatory Phase III trial to validate its patient reported outcome measure. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription